STAGE IV URETER CANCER AJCC V8

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder or urinary tract cancer who cannot take standard cisplatin chemotherapy. About 72 adults with cancer that has spr…

This early-phase trial tests a combination of two drugs (erdafitinib and enfortumab vedotin) in about 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest dose and see if the combo can shrink or stabilize the…

This phase III trial tests whether adding cabozantinib to avelumab (an immunotherapy) helps people with metastatic urothelial cancer live longer than avelumab alone. About 654 participants who have already completed initial chemotherapy will receive either the combination or avel…

This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…

This study tests whether adding propranolol (a blood pressure drug) to standard immunotherapy can help people with advanced bladder cancer. It involves 6 adults whose cancer has spread or cannot be removed. The main goal is to check safety and see how the combination affects the …

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This study looks at whether certain gene mutations (ARID1A and KDM6A) and a protein called CXCL13 in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Only 6 participants with these specific gene changes…